{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T12:35:46Z","timestamp":1791117346978,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","goldjournal.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.urology.2008.06.067","type":"journal-article","created":{"date-parts":[[2008,9,26]],"date-time":"2008-09-26T04:30:35Z","timestamp":1222403435000},"page":"1061-1067","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB"],"prefix":"10.1016","volume":"72","author":[{"given":"Claus G.","family":"Roehrborn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph T.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Bavendam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghong","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urology.2008.06.067_bib1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-5347(01)65075-4","article-title":"The International Continence Society \u201cBenign Prostatic Hyperplasia\u201d study: The bothersomeness of urinary symptoms","volume":"157","author":"Peters","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib3","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib4","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S1474-4422(03)00622-7","article-title":"Antimuscarinics for the treatment of overactive bladder","volume":"3","author":"Andersson","year":"2004","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.urology.2008.06.067_bib5","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0022-5347(05)00483-0","article-title":"Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction","volume":"175","author":"Abrams","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib6","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1097\/01.ju.0000181823.33224.a0","article-title":"Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"174","author":"Kaplan","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.urology.2006.03.006","article-title":"Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia","volume":"68","author":"Kaplan","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urology.2008.06.067_bib8","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1464-410X.2006.06068.x","article-title":"Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2008.06.067_bib9","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: A randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2008.06.067_bib10","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1464-410X.2006.06574.x","article-title":"The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis","volume":"99","author":"Blake-James","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2008.06.067_bib11","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.eururo.2006.10.005","article-title":"Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder","volume":"51","author":"Dmochowski","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib12","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0090-4295(98)00655-4","article-title":"Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia","volume":"53","author":"Roehrborn","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urology.2008.06.067_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-5347(05)67962-1","article-title":"Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia: Proscar Long-term Efficacy and Safety Study","volume":"163","author":"Roehrborn","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib14","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0090-4295(99)00232-0","article-title":"Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: Results of a four-year, randomized trial comparing finasteride versus placebo","volume":"54","author":"Roehrborn","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urology.2008.06.067_bib15","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0022-5347(05)00708-1","article-title":"Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo","volume":"175","author":"Crawford","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib16","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0022-5347(05)00408-8","article-title":"Tracking of longitudinal changes in measures of benign prostatic hyperplasia in a population based cohort","volume":"175","author":"St. Sauver","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib17","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0090-4295(99)00209-5","article-title":"Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia","volume":"54","author":"Bruskewitz","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urology.2008.06.067_bib18","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0090-4295(01)01155-4","article-title":"Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials","volume":"58","author":"Roehrborn","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.urology.2008.06.067_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0302-2838(02)00210-5","article-title":"Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes","volume":"42","author":"Roehrborn","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1471-2288-6-18","article-title":"Multivariable risk prediction can greatly enhance the statistical power of clinical trial subgroup analysis","volume":"6","author":"Hayward","year":"2006","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.urology.2008.06.067_bib21","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1001\/jama.298.10.1209","article-title":"Limitations of applying summary results of clinical trials to individual patients: The need for risk stratification","volume":"298","author":"Kent","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.urology.2008.06.067_bib22","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0302-2838(03)00384-1","article-title":"Prostate-specific antigen as an estimator of prostate volume in the management of patients with symptomatic benign prostatic hyperplasia","volume":"44","author":"Mochtar","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.urology.2008.06.067_bib23","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1046\/j.1464-410X.2003.04310.x","article-title":"Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5\u03b1-reductase inhibitor","volume":"92","author":"O'Leary","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2008.06.067_bib24","unstructured":"Coyne KS, Matza L, Thompson C, et al. A comparison of three approaches to analyze urinary urgency as a treatment outcome. Presented at 35th Annual Meeting of the International Continence Society, August 28-September 2, 2005, Montreal, Quebec, Canada."},{"key":"10.1016\/j.urology.2008.06.067_bib25","unstructured":"Coyne KS, Matza L, Thompson C, et al. From an OAB patient perspective: Health-related quality of life improves when frequency and urgency improve. Presented at 35th Annual Meeting of the International Continence Society, August 28-September 2, 2005, Montreal, Quebec, Canada."},{"key":"10.1016\/j.urology.2008.06.067_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.urology.2006.03.006","article-title":"Tolterodine extended release improves overactive bladder symptoms in men with overactive bladder and nocturia","volume":"68","author":"Kaplan","year":"2006","journal-title":"Urology"},{"issue":"suppl 4","key":"10.1016\/j.urology.2008.06.067_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1464-410X.2005.05485.x","article-title":"Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Latest update on alpha-adrenoceptor antagonists","volume":"95","author":"Milani","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.urology.2008.06.067_bib28","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urology.2008.06.067_bib29","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0090-4295(98)00654-2","article-title":"Serum prostate-specific antigen concentration is a powerful predictor of acute urinary retention and need for surgery in men with clinical benign prostatic hyperplasia","volume":"53","author":"Roehrborn","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.urology.2008.06.067_bib30","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1046\/j.1464-410x.1999.00966.x","article-title":"Prevalence of lower urinary tract symptoms and self-reported diagnosed \u201cbenign prostatic hyperplasia,\u201d and their effect on quality of life in a community-based survey of men in the UK","volume":"83","author":"Trueman","year":"1999","journal-title":"BJU Int"}],"container-title":["Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429508008777?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090429508008777?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:49:13Z","timestamp":1758764953000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090429508008777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0090429508008777"],"URL":"https:\/\/doi.org\/10.1016\/j.urology.2008.06.067","relation":{},"ISSN":["0090-4295"],"issn-type":[{"value":"0090-4295","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Serum PSA on Efficacy of Tolterodine Extended Release With or Without Tamsulosin in Men With LUTS, Including OAB","name":"articletitle","label":"Article Title"},{"value":"Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urology.2008.06.067","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}